Medtech M&A may pick up after mixed start to 2024, analysts

The annual number of medtech acquisitions is on course to slump to its lowest level since 2017, Needham analysts said Friday.
At the midpoint of the year, deal volumes are down but values are up. The analysts see the potential for increased activity, citing stabilizing interest rates and low valuations. Still, they identified antitrust concerns as a barrier that could persist until at least the presidential election.